5068202025-01-012025-03-315068202025-03-315068202024-03-315068202024-04-012025-03-315068202025-01-012025-03-31in-capmkt:OtherExpenses1Member5068202025-01-012025-03-31in-capmkt:OtherExpenses2Member5068202025-01-012025-03-31in-capmkt:OtherExpenses3Member5068202024-04-012025-03-31in-capmkt:OtherExpenses1Member5068202024-04-012025-03-31in-capmkt:OtherExpenses2Member5068202024-04-012025-03-31in-capmkt:OtherExpenses3Member5068202025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15068202024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15068202025-01-012025-03-31RelatedPartyTransactionDomain15068202024-12-31RelatedPartyTransactionDomain15068202025-03-31RelatedPartyTransactionDomain15068202025-01-012025-03-31RelatedPartyTransactionDomain25068202024-12-31RelatedPartyTransactionDomain25068202025-03-31RelatedPartyTransactionDomain25068202025-01-012025-03-31RelatedPartyTransactionDomain35068202024-12-31RelatedPartyTransactionDomain35068202025-03-31RelatedPartyTransactionDomain35068202025-01-012025-03-31RelatedPartyTransactionDomain45068202024-12-31RelatedPartyTransactionDomain45068202025-03-31RelatedPartyTransactionDomain45068202025-01-012025-03-31RelatedPartyTransactionDomain55068202024-12-31RelatedPartyTransactionDomain55068202025-03-31RelatedPartyTransactionDomain55068202025-01-012025-03-31RelatedPartyTransactionDomain65068202024-12-31RelatedPartyTransactionDomain65068202025-03-31RelatedPartyTransactionDomain65068202025-01-012025-03-31RelatedPartyTransactionDomain75068202024-12-31RelatedPartyTransactionDomain75068202025-03-31RelatedPartyTransactionDomain75068202025-01-012025-03-31RelatedPartyTransactionDomain85068202024-12-31RelatedPartyTransactionDomain85068202025-03-31RelatedPartyTransactionDomain85068202025-01-012025-03-31RelatedPartyTransactionDomain95068202024-12-31RelatedPartyTransactionDomain95068202025-03-31RelatedPartyTransactionDomain95068202025-01-012025-03-31RelatedPartyTransactionDomain105068202024-12-31RelatedPartyTransactionDomain105068202025-03-31RelatedPartyTransactionDomain105068202025-01-012025-03-31RelatedPartyTransactionDomain115068202024-12-31RelatedPartyTransactionDomain115068202025-03-31RelatedPartyTransactionDomain115068202025-01-012025-03-31RelatedPartyTransactionDomain125068202024-12-31RelatedPartyTransactionDomain125068202025-03-31RelatedPartyTransactionDomain125068202025-01-012025-03-31RelatedPartyTransactionDomain135068202024-12-31RelatedPartyTransactionDomain135068202025-03-31RelatedPartyTransactionDomain135068202025-01-012025-03-31RelatedPartyTransactionDomain145068202024-12-31RelatedPartyTransactionDomain145068202025-03-31RelatedPartyTransactionDomain145068202025-01-012025-03-31RelatedPartyTransactionDomain155068202024-12-31RelatedPartyTransactionDomain155068202025-03-31RelatedPartyTransactionDomain155068202025-01-012025-03-31RelatedPartyTransactionDomain165068202024-12-31RelatedPartyTransactionDomain165068202025-03-31RelatedPartyTransactionDomain165068202025-01-012025-03-31RelatedPartyTransactionDomain175068202024-12-31RelatedPartyTransactionDomain175068202025-03-31RelatedPartyTransactionDomain175068202025-01-012025-03-31RelatedPartyTransactionDomain185068202024-12-31RelatedPartyTransactionDomain185068202025-03-31RelatedPartyTransactionDomain185068202025-01-012025-03-31RelatedPartyTransactionDomain195068202024-12-31RelatedPartyTransactionDomain195068202025-03-31RelatedPartyTransactionDomain195068202025-01-012025-03-31RelatedPartyTransactionDomain205068202024-12-31RelatedPartyTransactionDomain205068202025-03-31RelatedPartyTransactionDomain205068202025-01-012025-03-31RelatedPartyTransactionDomain215068202024-12-31RelatedPartyTransactionDomain215068202025-03-31RelatedPartyTransactionDomain215068202025-01-012025-03-31RelatedPartyTransactionDomain225068202024-12-31RelatedPartyTransactionDomain225068202025-03-31RelatedPartyTransactionDomain225068202025-01-012025-03-31RelatedPartyTransactionDomain235068202024-12-31RelatedPartyTransactionDomain235068202025-03-31RelatedPartyTransactionDomain235068202025-01-012025-03-31RelatedPartyTransactionDomain245068202024-12-31RelatedPartyTransactionDomain245068202025-03-31RelatedPartyTransactionDomain245068202025-01-012025-03-31RelatedPartyTransactionDomain255068202024-12-31RelatedPartyTransactionDomain255068202025-03-31RelatedPartyTransactionDomain255068202025-01-012025-03-31RelatedPartyTransactionDomain265068202024-12-31RelatedPartyTransactionDomain265068202025-03-31RelatedPartyTransactionDomain265068202025-01-012025-03-31RelatedPartyTransactionDomain275068202024-12-31RelatedPartyTransactionDomain275068202025-03-31RelatedPartyTransactionDomain275068202025-01-012025-03-31RelatedPartyTransactionDomain285068202024-12-31RelatedPartyTransactionDomain285068202025-03-31RelatedPartyTransactionDomain285068202025-01-012025-03-31RelatedPartyTransactionDomain295068202024-12-31RelatedPartyTransactionDomain295068202025-03-31RelatedPartyTransactionDomain295068202025-01-012025-03-31RelatedPartyTransactionDomain305068202024-12-31RelatedPartyTransactionDomain305068202025-03-31RelatedPartyTransactionDomain305068202025-01-012025-03-31RelatedPartyTransactionDomain315068202024-12-31RelatedPartyTransactionDomain315068202025-03-31RelatedPartyTransactionDomain315068202025-01-012025-03-31RelatedPartyTransactionDomain325068202024-12-31RelatedPartyTransactionDomain325068202025-03-31RelatedPartyTransactionDomain325068202025-01-012025-03-31RelatedPartyTransactionDomain335068202024-12-31RelatedPartyTransactionDomain335068202025-03-31RelatedPartyTransactionDomain335068202025-01-012025-03-31RelatedPartyTransactionDomain345068202024-12-31RelatedPartyTransactionDomain345068202025-03-31RelatedPartyTransactionDomain345068202025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares506820ASTRAZENNAINE203A01020ASTRAZENECA PHARMA INDIA LIMITEDMain BoardEquity2024-04-012025-03-312025-05-302025-05-16INRMillionsQuarterlyFourth quarterSingle segmentHealthcare2025-05-3014:30:002025-05-3017:00:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-02-11https://www.astrazeneca.in/content/dam/az-in/pdf/2025/investor_relations_section_DU/Policy%20on%20Related%20Party%20Transactions.pdffalsefalseThe disclosure for the default on loans and debt securities is not applicable to the entity.2025-01-012025-03-31AuditedStandalone480480000016150000049663000009425000002878600000-122500000066070000068000001769000006843000004124800000841500000-56800000784700000229200000-27000000202200000058250000000005825000001460000059710000050000000223.323.30023.323.3Notes: <BR> 1. The Statements of Financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India. <BR> 2. The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. <BR> 3. Exceptional Items <BR> a) Exceptional items for the year ended 31 March 2025 consists of employee separation cost amounting to Rs. 331.5 Million for restructuring of Biopharmaceuticals Business Unit in line with strategy of the Company to become a specialist focussed organisation, bring innovative medicines faster and transform patient outcome. <BR> b) During the previous year, the Company had made an announcement to Stock exchanges about its intention to exit the Company’s manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. The operations at the manufacturing site is continuing as at March 31, 2025 and is expected to cease during the financial year 2025-26.The Company has estimated and accounted for expense amounting to Rs.56.8 Million for the quarter ended March 31, 2025 and Rs.636.4 Million in relation to the closure of manufacturing site, in accordance with the relevant Indian accounting standards. <BR> c) The Company had entered into an Advance Pricing Agreement with Central Board of Direct Taxation for financial years 2015-2016 to 2019-2020 for which there were certain previously disclosed disputed Transfer Pricing matters consequent to which an amount of Rs.164.3 Million is disclosed as an exceptional income for the year ended 31 March 2024. <BR> 4. The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial years and the published unaudited year-to-date figures up to the third quarter of the respective financial years which were subjected to limited review by the statutory auditors. <BR> 5. The Board of Directors, at its meeting dated 30 May 2025, have recommended a final dividend of Rs. 32 per equity share aggregating to Rs. 800 Million which is subject to approval of shareholders at the ensuing Annual General Meeting . <BR> 6. This Statement of financial results, Statement of assets and liabilities and Statement of cash flows were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 30 May 2025. <BR> 7. The Company has decided to change the rounding off principle followed in the Statement of financial results from lakhs of rupees to millions of rupees from the quarter ended 30 June 2024. <BR> <BR> <BR> For AstraZeneca Pharma India Limited <BR> <BR> <BR> Sanjeev Kumar Panchal <BR> Managing Director <BR> 2024-04-012025-03-31AuditedStandalone1716290000040630000017569200000287130000010088200000-33294000002574400000146000003999000002418700000150377000002531500000-9679000001563600000605400000-1992000004062000000115740000000001157400000-117000001145700000500000002765330000046.346.30046.346.3Allowance for expected credit loss (net)-9400000Selling, marketing and distribution expenses220200000Other Expenses473500000Allowance for expected credit loss (net)6600000Selling, marketing and distribution expenses848700000Other Expenses1563400000635800000000660000000000110000080300000814000004156000006183000001757700000548500000001848800000536140000056000003000000158000000737680000005617000001342350000000151812000005000000076535000007703500000770350000000002945000002945000006320000000900000004477000000253000004537700000456300000031550000048785000009798000001065300000106400000070300000000074777000001518120000014600000-3206200000-3168000000-28260000000-525000000259800000002927000000399900000460000034000000-682000000-740000003156000005140000000-320000006198000000-26810000012955000000006419000000653600000000000007100000175000000000000000000000003184000000030800000000000000005530000060000000060000000-655900000305700000030570000050557000005361400000Re-measurement gains/(losses) on post employment benefit obligations1960000019600000Re-measurement gains/(losses) on post employment benefit obligations-15600000-156000005000000-39000000014600000-11700000AstraZeneca Pharma India Limited******AstraZeneca UK Limited, United Kingdom******Holding Company of AstraZeneca Treasury Limited, United KingdomPurchase of goods or servicesNA48992000009631800002236900000AstraZeneca Pharma India Limited******AstraZeneca AB, Sweden******Holding Company of AstraZeneca Pharmaceuticals AB, SwedenSale of goods or servicesNA631900000199240000378800000AstraZeneca Pharma India Limited******AstraZeneca AB, Sweden******Holding Company of AstraZeneca Pharmaceuticals AB, SwedenPurchase of goods or servicesNA1452300000452480000654600000AstraZeneca Pharma India Limited******AstraZeneca UK Limited, United Kingdom******Holding Company of AstraZeneca Treasury Limited, United KingdomAny other transactionPayment towards reimbursement of expensesNA990000000AstraZeneca Pharma India Limited******AstraZeneca Pty Ltd, Australia******Fellow subsidiaryAny other transactionPayment towards reimbursement of expensesNA000AstraZeneca Pharma India Limited******AstraZeneca UK Limited, United Kingdom******Holding Company of AstraZeneca Treasury Limited, United KingdomAny other transactionRecovery of reimbursable expensesNA12550000066750000102300000AstraZeneca Pharma India Limited******AstraZeneca FZ LLC, Dubai******Fellow subsidiaryAny other transactionRecovery of reimbursable expensesNA400000086100000AstraZeneca Pharma India Limited******AstraZeneca Singapore Pte Ltd, Singapore******Fellow subsidiaryAny other transactionRecovery of reimbursable expensesNA840000030600005300000AstraZeneca Pharma India Limited******AstraZeneca Pharmaceuticals (Pty) Limited, South Africa******Fellow subsidiaryAny other transactionRecovery of reimbursable expensesNA630000006300000AstraZeneca Pharma India Limited******AstraZeneca Pharmaceuticals (Phils) Inc, Philippines******Fellow subsidiaryAny other transactionRecovery of reimbursable expensesNA000AstraZeneca Pharma India Limited******AstraZeneca UK Limited, United Kingdom******Holding Company of AstraZeneca Treasury Limited, United KingdomAny other transactionEmployee Share Compensation expensesNA-410000040900000AstraZeneca Pharma India Limited******P.T. AstraZeneca Indonesia******Fellow subsidiaryAny other transactionRecovery of reimbursable expensesNA520000037800003400000AstraZeneca Pharma India Limited******AstraZeneca Pharmaceuticals Limited, Kenya******Fellow subsidiaryAny other transactionRecovery of reimbursable expensesNA820000006400000AstraZeneca Pharma India Limited******AstraZeneca Pharma India Limited Employees Gratuity Fund Trust******Employees' Benefit PlanAny other transactionContribution to TrustNA000AstraZeneca Pharma India Limited******AstraZeneca Pharma India Limited Management Staff Provident Fund Trust******Employees' Benefit PlanAny other transactionContribution to TrustNA6800000000AstraZeneca Pharma India Limited******AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust******Employees' Benefit PlanAny other transactionContribution to TrustNA360000000AstraZeneca Pharma India Limited******Mr. Sanjeev Kumar Panchal******Managing DirectorAny other transactionShort term Employee BenefitsNA2530000000AstraZeneca Pharma India Limited******Mr. Sanjeev Kumar Panchal******Managing DirectorAny other transactionLong term Employee BenefitsNA130000000AstraZeneca Pharma India Limited******Mr. Sanjeev Kumar Panchal******Managing DirectorAny other transactionPost Employment BenefitNA-2020000000AstraZeneca Pharma India Limited******Mr. Sanjeev Kumar Panchal******Managing DirectorAny other transactionEmployee Share Compensation ExpensesNA660000000AstraZeneca Pharma India Limited******Ms. Bhavana Agarwal******Director and Chief Financial OfficerAny other transactionShort term Employee BenefitsNA1370000000AstraZeneca Pharma India Limited******Ms. Bhavana Agarwal******Director and Chief Financial OfficerAny other transactionLong term Employee BenefitsNA40000000AstraZeneca Pharma India Limited******Ms. Bhavana Agarwal******Director and Chief Financial OfficerAny other transactionPost Employment BenefitNA-10000000AstraZeneca Pharma India Limited******Ms. Bhavana Agarwal******Director and Chief Financial OfficerAny other transactionEmployee Share Compensation ExpensesNA30000000AstraZeneca Pharma India Limited******Ms. Manasa. R******Company SecretaryAny other transactionShort term Employee BenefitsNA200000000AstraZeneca Pharma India Limited******Ms. Manasa. R******Company SecretaryAny other transactionLong term Employee BenefitsNA10000000AstraZeneca Pharma India Limited******Ms. Manasa. R******Company SecretaryAny other transactionPost Employment BenefitNA-70000000AstraZeneca Pharma India Limited******Ms. Manasa. R******Company SecretaryAny other transactionEmployee Share Compensation ExpensesNA000AstraZeneca Pharma India Limited******Mr. Narayan K Seshadri******Independent DirectorAny other transactionSitting fees paid to independent directorsNA20000000AstraZeneca Pharma India Limited******Ms. Revathy Ashok******Independent DirectorAny other transactionSitting fees paid to independent directorsNA160000000AstraZeneca Pharma India Limited******Ms. Shilpa Divekar Nirula******Independent DirectorAny other transactionSitting fees paid to independent directorsNA110000000AstraZeneca Pharma India Limited******Ms. Monica Widhani******Independent DirectorAny other transactionSitting fees paid to independent directorsNA50000000AstraZeneca Pharma India Limited******AstraZeneca Pharmaceuticals AB, Sweden******Holding CompanyAny other transactionDividend PaidNA45000000000AstraZeneca Pharma India Limited******Ms. Monica Widhani******Independent DirectorAny other transactionDividend PaidNA0007700500000AuditedtruePrice Waterhouse & Co Chartered Accountants LLPtrue2026-11-30